RE:New Press Release - Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic CancerThis press release now has the world learning what we know --- that ONCY's drug platform pelareorep in combination with immune checkpoint inhibitors is effective in the expanded treatment of the orphan/rare disease of pancreatic cancer.
We already know that ONCY's pelareorep is ready for a Phase registration study in the for the orphan disease and unmet treatment need of metastatic pancreatic cancer (PDAC) with an immune checkpoint inhibitor plus chemotherapy. Now ONCY and PanCan have expanded the pancreatic program to include earlier diagnosed and younger patients.